Minimal increase in COVID-19 mortality is seen in patients taking insulin, alpha-glucosidase inhibitors, and DPP inhibitors compared to other glucose-lowering medications. Difference is thought to be due to increased severity of disease in patients associated with increased risk of mortality. The gene discussed is GAA; the disease is COVID-19.